Paper32967006
SARS-CoV-2 vaccines in development.
Krammer F. Nature, 2020. Cited by 1,502 papers, by iCite.
Cite this record
ConductScience Library. SARS-CoV-2 vaccines in development. Papers, record 32967006. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32967006
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Coronavirus Infections | Major topic |
| Drug Development | Major topic |
| Pandemics | Major topic |
| Pneumonia, Viral | Major topic |
| Viral Vaccines | Major topic |
| Animals | |
| COVID-19 | |
| COVID-19 Vaccines | |
| Clinical Trials as Topic | |
| Drug Industry | |
| Humans | |
| Immunity, Mucosal |
Source PubMed
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT04854876 | Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC as an Immune System Enhancer Along With Vaccination Against COVID-19 | Background | ClinicalTrials.gov | |
| NCT04944095 | Change in Antibody Levels Following SARS-CoV-2 (Covid-19) Vaccinations | Background | ClinicalTrials.gov |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 33881342 | Infection and Inflammation of Genitourinary Tract. | https://conductscience.org/library/papers/33881342 |
Source PubMed
References87
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32785213 | Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. | Nature | 2020 | https://conductscience.org/library/papers/32785213 | PubMed |
| 2 | 26655630 | Evaluation of the attenuation, immunogenicity, and efficacy of a live virus vaccine generated by codon-pair bias de-optimization of the 2009 pandemic H1N1 influenza virus, in ferrets. | Vaccine | 2016 | https://conductscience.org/library/papers/26655630 | PubMed |
| 3 | 32516797 | Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. | Nature | 2020 | https://conductscience.org/library/papers/32516797 | PubMed |
| 4 | 15650185 | Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event. | J Virol | 2005 | https://conductscience.org/library/papers/15650185 | PubMed |
| 5 | 32801356 | A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice. | Cell Res | 2020 | https://conductscience.org/library/papers/32801356 | PubMed |
| 6 | 32015507 | A pneumonia outbreak associated with a new coronavirus of probable bat origin. | Nature | 2020 | https://conductscience.org/library/papers/32015507 | PubMed |
| 7 | 32075877 | Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. | Science | 2020 | https://conductscience.org/library/papers/32075877 | PubMed |
| 8 | 32591393 | A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. | J Immunol | 2020 | https://conductscience.org/library/papers/32591393 | PubMed |
| 9 | 28807998 | Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. | Proc Natl Acad Sci U S A | 2017 | https://conductscience.org/library/papers/28807998 | PubMed |
| 10 | 23261045 | High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season. | Vaccine | 2013 | https://conductscience.org/library/papers/23261045 | PubMed |
| 11 | 33073694 | Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection. | Emerg Microbes Infect | 2020 | https://conductscience.org/library/papers/33073694 | PubMed |
| 12 | 32789505 | Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. | JAMA | 2020 | https://conductscience.org/library/papers/32789505 | PubMed |
| 13 | 33232870 | Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. | EBioMedicine | 2020 | https://conductscience.org/library/papers/33232870 | PubMed |
| 14 | 32611917 | Evaluation of the susceptibility of mice & hamsters to SARS-CoV-2 infection. | Indian J Med Res | 2020 | https://conductscience.org/library/papers/32611917 | PubMed |
| 15 | 32616673 | Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. | Science | 2020 | https://conductscience.org/library/papers/32616673 | PubMed |
| 16 | 32731258 | ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. | Nature | 2020 | https://conductscience.org/library/papers/32731258 | PubMed |
| 17 | 32722908 | Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32722908 | PubMed |
| 18 | 32702298 | Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. | Lancet | 2020 | https://conductscience.org/library/papers/32702298 | PubMed |
| 19 | 17049691 | Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro. | Vaccine | 2007 | https://conductscience.org/library/papers/17049691 | PubMed |
| 20 | 33139139 | NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. | Vaccine | 2020 | https://conductscience.org/library/papers/33139139 | PubMed |
Cited by1,207
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,502 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42975794 | Non-covalent inhibitors targeting SARS-CoV-2 3CLpro: structural insights and developmental landscape. | Arch Pharm Res | 2026 | https://conductscience.org/library/papers/42975794 | PubMed |
| 42903854 | Comparison of antigen-specific B cell responses reveals disparity in immunogenicity and memory B cell formation across COVID-19 vaccine platforms. | Hlife | 2024 | https://conductscience.org/library/papers/42903854 | PubMed |
| 42794550 | Evaluation of the Antiviral Activity of Cuscuta Extracts Against HSV-1, HSV-2 (ACV-Resistant Strain), HCoV229E and SARS-CoV-2. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42794550 | PubMed |
| 42709284 | Nanomedicine beyond carriers - devices, cells & living therapeutics. | Biomed Microdevices | 2026 | https://conductscience.org/library/papers/42709284 | PubMed |
| 42706242 | Dynamics of neutralizing antibody responses after trivalent XBB.1.5 booster vaccination: a 480-day longitudinal study. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42706242 | PubMed |
| 42682883 | Host cell entry receptors as pharmacological targets in respiratory viral infections: from biology to clinical translation. | Front Cell Infect Microbiol | 2026 | https://conductscience.org/library/papers/42682883 | PubMed |
| 42646679 | Safety and Immunogenicity of an Additional Dose of Thailand Government Pharmaceutical Organization (GPO) Inactivated NDV-HXP-S COVID-19 Vaccine (HXP-GPOVac) Administered After Primary Vaccination with HXP-GPOVac or BNT162b2: An Open-Label Phase II Extension Trial in Thai Adults. | Vaccines (Basel) | 2026 | https://conductscience.org/library/papers/42646679 | PubMed |
| 42618711 | Vaccination-first immune priming shapes a sustained mRNA vaccine-induced IgG4 class switch that associates with SARS-CoV-2 breakthrough infection risk. | Sci Rep | 2026 | https://conductscience.org/library/papers/42618711 | PubMed |
| 42506648 | Six Years of COVID-19: Lessons from Epidemiology, Vaccination Campaigns, Clinical Risk Stratification, and Thromboembolic Surveillance. | Vaccines (Basel) | 2026 | https://conductscience.org/library/papers/42506648 | PubMed |
| 42506597 | Emerging Viral Zoonoses: Epidemiology, Vaccination Strategies, and Implications for Global Public Health. | Vaccines (Basel) | 2026 | https://conductscience.org/library/papers/42506597 | PubMed |
| 42498827 | Immunogenicity and safety of BNT162b2 vaccine in patients with juvenile immune mediated inflammatory disease. | Pediatr Res | 2026 | https://conductscience.org/library/papers/42498827 | PubMed |
| 42489461 | Respiratory mucosal vaccines for emerging viruses: promise and challenges. | J Virol | 2026 | https://conductscience.org/library/papers/42489461 | PubMed |
| 42467983 | The critical role of artificial intelligence and bioinformatics in accelerating peptide-based vaccine discovery for tackling global infectious diseases. | Brief Bioinform | 2026 | https://conductscience.org/library/papers/42467983 | PubMed |
| 42430655 | Eras of bioinformatics technologies from command-line interfaces to artificial intelligence (AI) chatbots. | Brief Bioinform | 2026 | https://conductscience.org/library/papers/42430655 | PubMed |
| 42371831 | Cytokine Profiles in Peripheral Blood Mononuclear Cells and Neutrophils following SARS-CoV-2 Vaccination: A Study from Kuwait. | Med Princ Pract | 2026 | https://conductscience.org/library/papers/42371831 | PubMed |
| 42347602 | Safety and Immunogenicity of a Locally Produced Inactivated NDV-HXP-S COVID-19 Vaccine (HXP-GPOVac) Compared with BNT162b2: A Phase II Randomized, Controlled, Double-Blind Noninferiority Trial in Thai Adults. | Vaccines (Basel) | 2026 | https://conductscience.org/library/papers/42347602 | PubMed |
| 42311421 | Nanotechnology-Enhanced Vaccines for Respiratory Infections: Opportunities and Challenges. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42311421 | PubMed |
| 42188806 | Immune Cell Signaling in Feline Infectious Peritonitis Virus Infection and Implications for Vaccine Design. | Vaccines (Basel) | 2026 | https://conductscience.org/library/papers/42188806 | PubMed |
| 42188772 | Intranasal Immunization with Live-Attenuated RSV-Vectored SARS-CoV-2 Vaccines Elicits Antigen-Specific Systemic and Mucosal Immunity and Protects Against Viral Challenge and Natural Infection. | Vaccines (Basel) | 2026 | https://conductscience.org/library/papers/42188772 | PubMed |
| 42181885 | Artificial intelligence for coordinating vaccine design, antiviral discovery, and real-world monitoring in the era of emerging and endemic viral threats. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42181885 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32967006
GET https://conductscience.org/api/papers/v1/32967006/references?page=2